There is a problem with the stock price data. Our supplier is working to solve the issue.
Stockholm Stock Exchange | Mid Cap
Calliditas
+52.44%
Latest
+47.36%
3 months
Kepler CheuvreuxCarnegieSEBPareto SecuritiesGuggenheim SecuritiesBryan GarnierCiti Investment ResearchKempenSEB Equities

About The Company

Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas